Patents by Inventor Frederique Bard

Frederique Bard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-TRANSTHYRETIN ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230391859
    Abstract: Provided herein are methods and compositions for detecting, reducing, and inhibiting misfolded transthyretin protein.
    Type: Application
    Filed: October 28, 2021
    Publication date: December 7, 2023
    Inventors: Frédérique Bard, Gene Kinney, Wagner Zago, Radhika Tripuraneni
  • Anti-Abeta Antibodies
    Publication number: 20230331828
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: September 12, 2022
    Publication date: October 19, 2023
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Anti-abeta antibodies
    Patent number: 11440953
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Grant
    Filed: April 20, 2022
    Date of Patent: September 13, 2022
    Assignee: OTHAIR PROTHENA LIMITED
    Inventors: Michael Skov, Tarlochan S. Nijjar, Frédérique Bard, Robin Barbour, Wagner Zago
  • Anti-Abeta antibodies
    Patent number: 11434284
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: September 6, 2022
    Assignee: OTHAIR PROTHENA LIMITED
    Inventors: Michael Skov, Tarlochan S. Nijjar, Frédérique Bard, Robin Barbour, Wagner Zago
  • Anti-abeta antibodies
    Patent number: 11434283
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: September 6, 2022
    Assignee: OTHAIR PROTHENA LIMITED
    Inventors: Michael Skov, Tarlochan S. Nijjar, Frédérique Bard, Robin Barbour, Wagner Zago
  • Anti-Abeta antibodies
    Patent number: 11434285
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Grant
    Filed: October 25, 2021
    Date of Patent: September 6, 2022
    Assignee: OTHAIR PROTHENA LIMITED
    Inventors: Michael Skov, Tarlochan S. Nijjar, Frédérique Bard, Robin Barbour, Wagner Zago
  • Anti-Abeta Antibodies
    Publication number: 20220242940
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: April 20, 2022
    Publication date: August 4, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Anti-Abeta Antibodies
    Publication number: 20220089762
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: October 25, 2021
    Publication date: March 24, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Anti-Abeta Antibodies
    Publication number: 20220049009
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: July 23, 2021
    Publication date: February 17, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Anti-Abeta Antibodies
    Publication number: 20220041701
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: October 25, 2021
    Publication date: February 10, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Anti-Abeta Antibodies
    Publication number: 20220041700
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: October 25, 2021
    Publication date: February 10, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Anti-Abeta Antibodies
    Publication number: 20220041699
    Abstract: Antibodies that bind human beta-amyloid peptide, methods of detecting, measuring and treating amyloidogenic disorders with said antibodies, pharmaceutical compositions comprising the antibodies and methods of manufacture are provided.
    Type: Application
    Filed: October 25, 2021
    Publication date: February 10, 2022
    Inventors: Michael SKOV, Tarlochan S. NIJJAR, Sridhar GOVINDARAJAN, Tom PURCELL, Mark WELCH, Frédérique BARD, Robin BARBOUR, Wagner ZAGO
  • Humanized antibodies that recognize beta amyloid peptide
    Patent number: 7871615
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include antibodies, e.g., humanized antibodies.
    Type: Grant
    Filed: June 1, 2004
    Date of Patent: January 18, 2011
    Assignees: Janssen Alzheimer Immunotherapy, Wyeth LLC
    Inventors: Guriq Basi, Jose Saldanha, Frédérique Bard
  • Method of screening an antibody for activity in clearing an amyloid deposit
    Patent number: 7575880
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: August 18, 2009
    Assignee: Elan Pharma International Limited
    Inventors: Dale B. Schenk, Frederique Bard, Theodore Yednock
  • ACTIVE IMMUNIZATION TO GENERATE ANTIBODIES TO SOLUBLE A-BETA
    Publication number: 20080279873
    Abstract: The invention provides methods useful for effecting prophylaxis or treatment of Alzheimer's disease. Such methods entail administering A-beta fragments from a central or C-terminal regions of A-beta. Such fragments can induce a polyclonal mixture of antibodies that specifically bind to soluble A-beta without binding to plaques. The antibodies can inhibit formation of amyloid deposits of A-beta in the brain of a patient from soluble A? thus preventing or treating the disease. Fragment A-beta 15-24 and subfragments of 5-10 contiguous amino acids thereof are preferred immunogens due to their capacity to generate a high titer of antibodies.
    Type: Application
    Filed: February 25, 2008
    Publication date: November 13, 2008
    Inventors: Peter A. Seubert, Nicki Vasquez, Frederique Bard, Ted Yednock
  • Prevention and treatment of amyloidogenic disease
    Publication number: 20060121038
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.
    Type: Application
    Filed: July 12, 2004
    Publication date: June 8, 2006
    Applicant: Neuralab Limited
    Inventors: Dale Schenk, Frederique Bard, Theodore Yednock
  • Prevention and treatment of amyloidogenic disease
    Publication number: 20050158304
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.
    Type: Application
    Filed: July 12, 2004
    Publication date: July 21, 2005
    Applicant: Neuralab Limited
    Inventors: Dale Schenk, Frederique Bard, Theodore Yednock
  • Prevention and treatment of amyloidogenic disease
    Publication number: 20050142132
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.
    Type: Application
    Filed: February 14, 2005
    Publication date: June 30, 2005
    Applicant: Neuralab Limited
    Inventors: Dale Schenk, Frederique Bard, Theodore Yednock
  • Prevention and treatment of amyloidogenic disease
    Publication number: 20050123544
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A? and antibodies binding to the same.
    Type: Application
    Filed: November 24, 2004
    Publication date: June 9, 2005
    Applicant: Neuralab Limited
    Inventors: Dale Schenk, Frederique Bard, Theodore Yednock
  • Humanized antibodies that recognize beta amyloid peptide
    Publication number: 20050118651
    Abstract: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A? in the brain of a patient. Preferred agents include antibodies, e.g., humanized antibodies.
    Type: Application
    Filed: June 1, 2004
    Publication date: June 2, 2005
    Applicants: Neuralab Limited, Wyeth
    Inventors: Guriq Basi, Jose Saldanha, Frederique Bard